2023 Fiscal Year Final Research Report
Development of innovative antitumor drugs that strongly induce phagocytosis of cancer cells by macrophages
| Project/Area Number |
22K19458
|
|---|
| Research Category |
Grant-in-Aid for Challenging Research (Exploratory)
|
| Allocation Type | Multi-year Fund |
|---|
| Review Section |
Medium-sized Section 50:Oncology and related fields
|
|---|
| Research Institution | Kobe University |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2022-06-30 – 2024-03-31
|
| Keywords | 抗体医薬 |
|---|
| Outline of Final Research Achievements |
CD47, a membrane molecule expressed on cancer cells, forms the intercellular signal CD47-SIRPα system by binding to SIRPα, a membrane molecule expressed on macrophages (MΦ). This CD47-SIRPα system strongly suppresses antibody-dependent cellular phagocytosis (ADCP) by MΦs. In this study, we tried to develop a new antibody drug that can strongly induce ADCP activity against tumors under conditions that inhibit the CD47-SIRPα system. We obtained antibodies that have the potential to exhibit antitumor effects against various types of tumors.
|
| Free Research Field |
生化学
|
| Academic Significance and Societal Importance of the Research Achievements |
本研究遂行の過程で得られた様々なデータには、MΦによる細胞貪食の制御機構について新たな知見をもたらす可能性があるものが含まれており、本研究の成果は学術的な観点から興味深いものであった。一方で、本研究では従来にない優れた抗腫瘍効果を示す抗体医薬の開発につながる成果を得ており、社会的意義のある成果となった。以上のことから、本研究の成果は基礎研究ならび革新的な治療薬開発に貢献することが期待できる成果であるといえる。
|
